Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Non Operating Income (2016 - 2025)

Spero Therapeutics' Non Operating Income history spans 10 years, with the latest figure at $376000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income rose 279.8% year-over-year to $376000.0; the TTM value through Dec 2025 reached $1.1 million, down 10.73%, while the annual FY2025 figure was $2.5 million, 4098.33% up from the prior year.
  • Non Operating Income reached $376000.0 in Q4 2025 per SPRO's latest filing, up from $2000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.2 million in Q2 2024 to a low of -$2.6 million in Q2 2022.
  • Average Non Operating Income over 5 years is $119600.0, with a median of $1500.0 recorded in 2025.
  • Peak YoY movement for Non Operating Income: crashed 2223.21% in 2022, then skyrocketed 3200.0% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$78000.0 in 2021, then surged by 1185.9% to $847000.0 in 2022, then tumbled by 99.65% to $3000.0 in 2023, then surged by 3200.0% to $99000.0 in 2024, then skyrocketed by 279.8% to $376000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Non Operating Income are $376000.0 (Q4 2025), $2000.0 (Q3 2025), and $744000.0 (Q2 2025).